DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
AZD-8848
2
Small molecule
Investigational
Unknown
Unknown
Rhinitis, Allergic, Seasonal
Toll-like receptor 7 agonist
AZD-8848
×
Maximum Phase:
2
First Approval:
None
UNII:
322ZMR6920
Molecule Type:
Small molecule
Molecular Formula:
C29H43N7O5
Molecular Weight:
569.71
AlogP:
2.21
PSA:
140.83
HBD:
2.0
HBA:
#RotB:
16.0
Source:
CP-461
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Renal Cell; Crohn Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Prostatic Neoplasms, Castration-Resistant
Unknown
CP-461
×
Maximum Phase:
2
First Approval:
None
UNII:
68OJX9I7DT
Molecule Type:
Small molecule
Molecular Formula:
C25H22ClFN2O
Molecular Weight:
420.92
AlogP:
5.25
PSA:
41.99
HBD:
1.0
HBA:
#RotB:
5.0
Source:
SLX-4090
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Hyperlipidemias; Hyperlipoproteinemia Type I; Hypertriglyceridemia
Microsomal triglyceride transfer protein inhibitor
SLX-4090
×
Maximum Phase:
2
First Approval:
None
UNII:
F84YQX13FV
Molecule Type:
Small molecule
Molecular Formula:
C31H25F3N2O4
Molecular Weight:
546.55
AlogP:
7.19
PSA:
67.87
HBD:
1.0
HBA:
#RotB:
5.0
Source:
PF-06823859
2
Unknown
Investigational
Unknown
Unknown
Dermatomyositis
Interferon beta inhibitor
PF-06823859
×
Maximum Phase:
2
First Approval:
None
UNII:
K2Q0JXS9B4
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-070
2
Antibody
Investigational
Unknown
Unknown
Unknown
Glutamate carboxypeptidase II other
MDX-070
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CURCUMINOIDS
2
Unknown
Investigational
Unknown
Unknown
Uveitis; Arthritis, Rheumatoid
Unknown
CURCUMINOIDS
×
Maximum Phase:
2
First Approval:
None
UNII:
R7T2XCO5ZU
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZ9773
2
Antibody
Investigational
Unknown
Unknown
Unknown
TNF-alpha inhibitor
AZ9773
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DOCUSATE
2
Small molecule
Investigational
Unknown
Unknown
Constipation; Gastroparesis
Surfactant laxative
DOCUSATE
×
Maximum Phase:
2
First Approval:
None
UNII:
M7P27195AG
Molecule Type:
Small molecule
Molecular Formula:
C20H38O7S
Molecular Weight:
422.58
AlogP:
4.15
PSA:
106.97
HBD:
1.0
HBA:
#RotB:
16.0
Source:
AG-13958
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Vascular endothelial growth factor receptor inhibitor
AG-13958
×
Maximum Phase:
2
First Approval:
None
UNII:
BK72RP7F7D
Molecule Type:
Small molecule
Molecular Formula:
C26H22FN7O
Molecular Weight:
467.51
AlogP:
5.31
PSA:
100.52
HBD:
3.0
HBA:
#RotB:
6.0
Source:
IMM-101
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
IMM-101
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CCX140
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CCX140
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RINUCUMAB
2
Antibody
Investigational
Unknown
Unknown
Macular Degeneration
Platelet-derived growth factor receptor beta inhibitor
RINUCUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
10E3O6YI4W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FORODESINE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Lymphoid; Lymphoma; Lymphoma, T-Cell, Peripheral; Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell
Purine nucleoside phosphorylase inhibitor
FORODESINE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
6SN82Y9U73
Molecule Type:
Small molecule
Molecular Formula:
C11H15ClN4O4
Molecular Weight:
302.72
AlogP:
-2.02
PSA:
134.26
HBD:
6.0
HBA:
#RotB:
2.0
Source:
[18F]D
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
[18F]D
×
Maximum Phase:
2
First Approval:
None
UNII:
Y1H4D2VKZD
Molecule Type:
Small molecule
Molecular Formula:
C22H27FN4O2
Molecular Weight:
398.48
AlogP:
3.77
PSA:
59.73
HBD:
0.0
HBA:
#RotB:
8.0
Source:
BMS-741672
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia
C-C chemokine receptor type 2 antagonist
BMS-741672
×
Maximum Phase:
2
First Approval:
None
UNII:
3UAA36FHF1
Molecule Type:
Small molecule
Molecular Formula:
C24H33F3N6O3S
Molecular Weight:
542.63
AlogP:
2.84
PSA:
107.53
HBD:
2.0
HBA:
#RotB:
7.0
Source:
VUPANORSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Hyperlipoproteinemia Type II; Lipodystrophy, Familial Partial
Angiopoietin like 3 (ANGPTL3) mRNA antisense inhibitor
VUPANORSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
A7YG62NHZ6
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL
2
Small molecule
Investigational
Unknown
Unknown
Sarcoma, Ewing
Unknown
DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL
×
Maximum Phase:
2
First Approval:
None
UNII:
6PHSP9EORV
Molecule Type:
Small molecule
Molecular Formula:
C65H116N6O21
Molecular Weight:
1317.66
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
MT-3995
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Non-alcoholic Fatty Liver Disease
Mineralocorticoid receptor antagonist
MT-3995
×
Maximum Phase:
2
First Approval:
None
UNII:
832663U2NB
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BL22
2
Antibody
Investigational
Unknown
Unknown
Lymphoma; Leukemia; Leukemia, Hairy Cell
CD22 binding agent
BL22
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TELISOTUZUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung
Hepatocyte growth factor receptor binding agent
TELISOTUZUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
976X9VXC3Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2
2
Unknown
Investigational
Unknown
Unknown
Colonic Neoplasms; Coronary Disease; Severe Acute Respiratory Syndrome
Unknown
RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2
×
Maximum Phase:
2
First Approval:
None
UNII:
3TTT9ZD93F
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CARFENTANIL
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia
Unknown
CARFENTANIL
×
Maximum Phase:
2
First Approval:
None
UNII:
LA9DTA2L8F
Molecule Type:
Small molecule
Molecular Formula:
C24H30N2O3
Molecular Weight:
394.51
AlogP:
3.68
PSA:
49.85
HBD:
0.0
HBA:
#RotB:
7.0
Source:
PAMAPIMOD
2
Small molecule
Investigational
Unknown
Unknown
Unknown
MAP kinase p38 alpha inhibitor
PAMAPIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
8S2C9V11K4
Molecule Type:
Small molecule
Molecular Formula:
C19H20F2N4O4
Molecular Weight:
406.39
AlogP:
1.94
PSA:
109.5
HBD:
3.0
HBA:
#RotB:
8.0
Source:
BRECANAVIR
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
HIV-1 protease inhibitor
BRECANAVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
E367I8C7FI
Molecule Type:
Small molecule
Molecular Formula:
C33H41N3O10S2
Molecular Weight:
703.84
AlogP:
3.87
PSA:
154.98
HBD:
2.0
HBA:
#RotB:
14.0
Source:
BMS-833923
2
Small molecule
Investigational
Unknown
Unknown
Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Esophageal Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Leukemia
Smoothened homolog antagonist
BMS-833923
×
Maximum Phase:
2
First Approval:
None
UNII:
41J7ZJ239R
Molecule Type:
Small molecule
Molecular Formula:
C30H27N5O
Molecular Weight:
473.58
AlogP:
6.32
PSA:
78.94
HBD:
3.0
HBA:
#RotB:
7.0
Source:
DAPIROLIZUMAB PEGOL
2
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
CD40 ligand inhibitor
DAPIROLIZUMAB PEGOL
×
Maximum Phase:
2
First Approval:
None
UNII:
N4606MB5HM
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUNOBINOP
2
Small molecule
Investigational
Unknown
Unknown
Pain; Sleep Initiation and Maintenance Disorders
Unknown
SUNOBINOP
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H33N3O3
Molecular Weight:
435.57
AlogP:
4.62
PSA:
75.43
HBD:
1.0
HBA:
#RotB:
3.0
Source:
PHENYLACETATE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
PHENYLACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EBDAROKIMAB
2
Antibody
Investigational
Unknown
Unknown
Psoriasis
Interleukin-12 inhibitor
EBDAROKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZEDENOLEUCEL
2
Cell
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Unknown
ZEDENOLEUCEL
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LAZUVAPAGON
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LAZUVAPAGON
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C27H32N4O3
Molecular Weight:
460.58
AlogP:
3.59
PSA:
87.46
HBD:
2.0
HBA:
#RotB:
5.0
Source:
SIMUROSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Cell division cycle 7-related protein kinase inhibitor
SIMUROSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
LST350G3XU
Molecule Type:
Small molecule
Molecular Formula:
C17H19N5OS
Molecular Weight:
341.44
AlogP:
2.84
PSA:
77.67
HBD:
2.0
HBA:
#RotB:
2.0
Source:
MESDOPETAM
2
Small molecule
Investigational
Unknown
Unknown
Parkinson Disease
Unknown
MESDOPETAM
×
Maximum Phase:
2
First Approval:
None
UNII:
HD4QV8GX26
Molecule Type:
Small molecule
Molecular Formula:
C12H18FNO3S
Molecular Weight:
275.35
AlogP:
1.61
PSA:
55.4
HBD:
1.0
HBA:
#RotB:
7.0
Source:
7-HYDROXYSTAUROSPORINE
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
7-HYDROXYSTAUROSPORINE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PF-4136309
2
Unknown
Investigational
Unknown
Unknown
Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal; Hepatitis C, Chronic; Osteoarthritis, Knee
C-C chemokine receptor type 2 antagonist
PF-4136309
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
198
199
200
201
202
203
204
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA